Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.5% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care Inc. (TNDM) operates in the diabetes care industry focusing on insulin pumps and continuous glucose monitoring systems. The sector is growing due to technological advancements and evolving patient preferences.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.5% on Apr 13, 2026 19:51

• TNDM stock started positively with a 5.69% gain, surpassing the S&P 500 performance.
• The optimistic outlook is supported by AI models suggesting favorable short-term sentiment and specific trading recommendations for large investors.
• In spite of a reduced price target by Goldman Sachs, TNDM stock remained strong, demonstrating robust confidence from investors in the company's potential for growth.
• Anticipated market expansion in diabetes care market by 2030, along with TNDM's innovative product range, likely influenced the market positively as investors foresee rising demand for diabetes care solutions.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

(TNDM) as a Liquidity Pulse for Institutional Tactics

This article analyzes Tandem Diabetes Care Inc. (NASDAQ: TNDM) using AI models to provide institutional trading strategies. It highlights a positive near-term sentiment with a mid-channel oscillation pattern and offers specific entry, target, and stop-loss zones for long, breakout, and short positions. The analysis includes multi-timeframe signal strengths and key support and resistance levels for various holding periods.

https://news.stocktradersdaily.com/news_release/91/TNDM_as_a_Liquidity_Pulse_for_Institutional_Tactics_041226112602_1776050762.html

Looking Ahead: Key Trends Shaping the Diabetes Care Market Until 2030

The diabetes care market is projected to reach $43.97 billion by 2030, growing at an 8.6% CAGR, driven by technological advancements and shifting patient preferences. Key trends include the adoption of digital health solutions, continuous glucose monitoring, and personalized treatment approaches. The market is segmented by product type (glucose monitoring and insulin pumps), diabetes type, and end-user, with major companies like F. Hoffmann-La Roche Ltd., Sanofi S.A., and Abbott Laboratories leading the industry.

https://www.openpr.com/news/4464028/looking-ahead-key-trends-shaping-the-diabetes-care-market-until

Goldman Sachs Lowers Price Target for Tandem Diabetes Care (TNDM) to $25 | TNDM Stock News

Goldman Sachs analyst David Roman has lowered the price target for Tandem Diabetes Care (TNDM) from $28 to $25, while maintaining a 'Neutral' rating. This adjustment reflects a more conservative outlook despite recent upgrades from other analysts. The average target price from 21 analysts is $30.86, suggesting a potential upside of 55.73% from its current price, while GuruFocus estimates a fair value of $35.47, indicating a 79.01% upside.

https://www.gurufocus.com/news/8785761/goldman-sachs-lowers-price-target-for-tandem-diabetes-care-tndm-to-25-tndm-stock-news

Tandem Diabetes Care Opens with 5.69% Gain, Outpacing S&P 500's 2.51% Increase

Tandem Diabetes Care, Inc. opened with a significant 5.69% gain, outperforming the S&P 500's 2.51% increase, despite a recent 1-month decline. The company faces challenges such as a low Return on Equity (0.30%), a quarterly net loss of -0.59 million USD, and a high debt-equity ratio of 100.99%. Technical indicators show mixed signals, with mildly bearish weekly trends but a mildly bullish monthly outlook, while institutional holdings stand at 100%.

https://www.marketsmojo.com/news/stocks-in-action/tandem-diabetes-care-opens-with-569-gain-outpacing-sp-500s-251-increase-3940132

TNDM Stock Chart | TANDEM DIABETES CARE INC (NASDAQ:TNDM)

The article provides a stock chart and current price information for TANDEM DIABETES CARE INC (NASDAQ:TNDM). It lists the stock's performance, including a slight decrease at closing and a small increase after hours. The page also categorizes various tools and resources available on ChartMill.com relevant to trading and investing.

https://www.chartmill.com/stock/quote/TNDM/stock-chart

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 7.5% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 6.6% Today

Ethereum ($ETH) Crypto Forecast: Up 7.4% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Solana ($SOL) Crypto Forecast: Up 5.1% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

KKR & Co. Inc. Class A ($KKR) Stock Forecast: Up 6.2% Today

Adobe Inc. ($ADBE) Stock Forecast: Up 5.2% Today

Accenture plc Class A (Ireland) ($ACN) Stock Forecast: Up 5.5% Today

Interactive Brokers Group, Inc. ($IBKR) Stock Forecast: Up 5.2% Today

Tandem Diabetes Care, Inc. Price History

10.02.2026 - TNDM Stock was up 6.2%

• Tandem Diabetes Care's positive momentum is due to the launch of the Mobi insulin pump for Android users, expanding accessibility and convenience.
• The company's strategic move to make its Control-IQ+ technology compatible with a broader range of devices aligns with the industry's shift toward smartphone-operated automated insulin delivery systems.
• Favorable analyst attention, such as a price target increase and stock rating upgrade, has bolstered investor confidence in Tandem Diabetes Care's growth potential.
• With the recent completion of a $265 million convertible bond offering, the company's funding and valuation landscape has been reshaped, offering flexibility for future growth but also raising concerns about potential share dilution. It is advisable for investors to monitor the company's utilization of these funds in comparison to its current financial performance.

19.02.2026 - TNDM Stock was up 5.6%

• Despite reporting a Q4 loss, Tandem Diabetes Care exceeded revenue expectations, showcasing strong growth in its top line.
• The exercise of Restricted Stock Units by company executives and insiders selling shares may have initially caused some downward pressure on the stock price.
• A stock upgrade by Piper Sandler and a positive market outlook contributed to the bullish movement, reflecting investor confidence in the company's future prospects.
• The detailed financial overview and competitor comparison provided insights into Tandem Diabetes Care's revenue sources and financial health, potentially reassuring investors and contributing to the positive market sentiment.

06.02.2026 - TNDM Stock was down 5.2%

• The expansion of Tandem's Mobi automated insulin delivery system to Android smartphones, while a positive development for accessibility and user convenience, may have raised concerns about potential competition in the market, leading to a bearish sentiment among investors.
• Despite receiving rating upgrades and achieving over $1 billion in worldwide sales, the market may have reacted negatively to the stock due to profit-taking by investors who were anticipating a bullish run following these positive developments.
• The announcement of further innovations planned for 2026, including a tubeless Mobi pump and an advanced insulin algorithm, could have created uncertainty among investors about the company's ability to maintain its current growth trajectory, contributing to the bearish movement in the stock price.

17.02.2026 - TNDM Stock was up 7.3%

• The positive movement in TNDM stock today could be linked to the company's new product releases, such as insulin pump software and the introduction of Tandem Mobi.
• Despite industry competition and economic challenges, TNDM's solid financial position and emphasis on advanced solutions appear to have appealed to investors.
• The recent net loss in the fourth quarter of 2025 might have been overlooked due to the perceived long-term growth prospects of Tandem Diabetes, contributing to the optimistic sentiment in the market today.

30.02.2026 - TNDM Stock was down 5.4%

• An amended Schedule 13G/A filing by The Vanguard Group, indicating 0 shares beneficially owned, could have triggered uncertainty among investors.
• An ongoing investigation by the Portnoy Law Firm regarding potential securities fraud linked to malfunctions in Tandem's insulin pumps likely impacted the company's product reliability and financial transparency, resulting in a stock price decline.
• Despite exceeding Q4 earnings estimates, a neutral recommendation from Mizuho and a consensus "Hold" rating from analysts may have contributed to the subdued sentiment surrounding Tandem Diabetes Care, aligning with the bearish market movement.
• The combination of the investigation, neutral recommendations, and the lack of clear bullish sentiments likely intensified selling pressure on TNDM shares, leading to the observable significant bearish movement.

08.03.2026 - TNDM Stock was up 5.6%

• The bullish movement in Tandem Diabetes Care's stock today could be attributed to the company's request for shareholder approval for an increase in shares to its Long-Term Incentive Plan, signaling confidence in its future growth prospects.
• The projected growth in the Smart Insulin Management Devices Market, where Tandem Diabetes Care is a key player, could have also positively impacted investor sentiment and contributed to the stock's rise.
• Despite a reduction in stake by a notable financial institution, the overall market seems optimistic about Tandem Diabetes Care's performance, especially with the upcoming announcement of its first-quarter 2026 financial results, which investors are eagerly anticipating for insights into the company's trajectory.

13.03.2026 - TNDM Stock was up 5.5%

• TNDM stock started positively with a 5.69% gain, surpassing the S&P 500 performance.
• The optimistic outlook is supported by AI models suggesting favorable short-term sentiment and specific trading recommendations for large investors.
• In spite of a reduced price target by Goldman Sachs, TNDM stock remained strong, demonstrating robust confidence from investors in the company's potential for growth.
• Anticipated market expansion in diabetes care market by 2030, along with TNDM's innovative product range, likely influenced the market positively as investors foresee rising demand for diabetes care solutions.

24.02.2026 - TNDM Stock was down 6.4%

• Despite recent positive developments, Tandem Diabetes Care (TNDM) saw a decrease in stock value.
• Investors may have been discouraged by the company's lack of profitability despite exceeding earnings and revenue projections, prompting some to realize profits.
• While analysts praised TNDM's pay-as-you-go pharmacy model, this alone may not have calmed market worries or profit expectations.
• The decline in stock value could be influenced by broader market trends or factors specific to Tandem Diabetes Care's industry performance.

27.02.2026 - TNDM Stock was down 6.9%

• Tandem Diabetes Care, Inc. experienced a bearish movement due to a significant 19.9% stock price drop following the disclosure of a malfunction in its insulin pumps.
• An investigation regarding potential securities fraud added further uncertainty and negative sentiment towards the company.
• The malfunction in the insulin pumps, which could lead to serious health complications for users, likely raised concerns among investors about the company's product safety and reliability.
• The market reacted strongly to the news, reflecting the importance of transparency and reliability in the healthcare technology sector.

07.03.2026 - TNDM Stock was up 6.2%

• Significant divestment of Tandem Diabetes Care shares by JPMorgan Chase & Co. initially raised investor concerns, but the market sentiment later turned positive.
• Despite Tandem Diabetes Care's ongoing lack of profitability, the stock witnessed a bullish trend leading up to the upcoming Q1 2026 financial results announcement.
• A mix of analyst opinions, resulting in a "Hold" consensus rating, and upgrades from some firms, likely influenced the positive investor sentiment as the company's potential was reassessed.
• Market enthusiasm and confidence in Tandem Diabetes Care's future performance, bolstered by beating earnings estimates for the quarter, drove the stock to a significant bullish movement.

07.03.2026 - TNDM Stock was down 5.8%

• The Smart Insulin Management Devices Market is projected to grow substantially by 2033, indicating a positive industry outlook. However, Tandem Diabetes Care's stock experienced a bearish trend.
• A reduction of 36.1% in Tandem Diabetes Care's stake by JPMorgan Chase & Co. could have contributed to the negative sentiment surrounding the stock.
• Despite beating earnings estimates, Tandem Diabetes Care remains unprofitable, leading to mixed analyst sentiment and a "Hold" consensus rating.
• The upcoming announcement of Tandem Diabetes Care's Q1 2026 results may have investors cautious, waiting for insights into the company's performance and future prospects before making investment decisions.

11.02.2026 - TNDM Stock was up 6.5%

• The bullish movement in TNDM stock today is due to the positive market reception of the company's expansion of the Mobi automated insulin delivery system to Android users. This move has significantly widened the potential user base for Tandem's technology, reflecting a strategic decision to tap into a larger market segment.
• Vanguard Group Inc.'s decision to trim its position in TNDM by 4.2% may have initially raised concerns among investors. However, the market sentiment was likely buoyed by the company's better-than-expected earnings report for the latest quarter, showcasing strong financial performance despite remaining unprofitable.
• The increased analyst attention, with Truist Securities raising its price target and Lake Street Capital Markets upgrading the stock to a Buy rating, also contributed to the positive momentum in TNDM stock, indicating growing confidence in the company's growth prospects and technological advancements in the diabetes management sector.
• Overall, Tandem Diabetes Care's strategic expansion into the Android market, coupled with favorable analyst ratings and robust financial performance, has fueled investor optimism and driven the bullish movement in the stock today.